Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Brawn Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹23.3 Mil.
Brawn Biotech's average Total Assets over the quarter that ended in Mar. 2026 was ₹208.6 Mil. Therefore, Brawn Biotech's annualized ROA % for the quarter that ended in Mar. 2026 was 11.19%.
The historical rank and industry rank for Brawn Biotech's ROA % or its related term are showing as below:
BOM:530207'
s ROA % Range Over the Past 10 Years
Min: -11.89 Med: -0.23 Max: 8.99
Current: 4.44
During the past 13 years, Brawn Biotech's highest ROA % was 8.99%. The lowest was -11.89%. And the median was -0.23%.
BOM:530207's ROA % is ranked better than 58.69% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.56
vs BOM:530207: 4.44
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Brawn Biotech ROA % Related Terms
Brawn Biotech ROA % Historical Data
* Premium members only.
The historical data trend for Brawn Biotech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brawn Biotech ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where Brawn Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Brawn Biotech (BOM:530207) has a ROA % of 11.19% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Brawn Biotech and its competitors. According to the industry distribution chart, Brawn Biotech ranks #416 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 41.3%.
Is Brawn Biotech's ROA % too high?
Brawn Biotech's current ROA % is 11.19%. The Drug Manufacturers industry median ROA % is 2.56. Brawn Biotech's value of 11.19% is 337.1% above this industry median. Based on the distribution chart, Brawn Biotech ranks #416 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Brawn Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brawn Biotech's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brawn Biotech ranks #416 out of 1007 companies for ROA %. This puts Brawn Biotech in the upper half of its industry. The industry median ROA % is 2.56. Brawn Biotech's value of 11.19% is 337.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.56, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brawn Biotech's current ROA % of 11.19% is 337.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Brawn Biotech and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brawn Biotech's current ROA % is 11.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brawn Biotech stock overvalued right now?
Based on GuruFocus' analysis, Brawn Biotech (BOM:530207) is currently considered Fairly Valued. The stock's GF Value™ is ₹20.49, compared to a current price of ₹21.00 — trading 2.5% above its estimated fair value. The current ROA % is 11.19% and 337.1% above the Drug Manufacturers industry median of 2.56. Brawn Biotech's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Brawn Biotech (BOM:530207), the current ROA % is 11.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brawn Biotech (BOM:530207) Overvalued in 2026?
Based on GuruFocus' analysis, Brawn Biotech stock appears to be overvalued.
The current stock price of ₹21.00 is trading 2.5% above its estimated GF Value™ of ₹20.49.
GuruFocus considers Brawn Biotech to be Fairly Valued.
Key valuation signals for BOM:530207:
ROA %: 11.19%
GF Value™: ₹20.49 vs. price of ₹21.00 (2.5% above fair value)
Industry Position: 337.1% above the Drug Manufacturers median (#416 of 1007)
No single metric tells the full story. See the BOM:530207 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brawn Biotech Ltd is a healthcare company. It is engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals.
55GF Score
Get the complete analysis for BOM:530207
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530207 has been successfully added to your 
